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AbstrAct
background Adverse events (AEs) epidemiology is 
the first step to improve practice in the healthcare 
system. Usually, the preferred method used to estimate 
the magnitude of the problem is the retrospective 
cohort study design, with retrospective reviews of the 
medical records. However this data collection involves a 
sophisticated sampling plan, and a process of intensive 
review of sometimes very heavy and complex medical 
records. Cross-sectional survey is also a valid and feasible 
methodology to study AEs.
Objectives The aim of this study is to compare AEs 
detection using two different methodologies: cross-
sectional versus retrospective cohort design.
setting Secondary and tertiary hospitals in five countries: 
Argentina, Colombia, Costa Rica, Mexico and Peru.
Participants The IBEAS Study is a cross-sectional survey 
with a sample size of 11 379 patients. The retrospective 
cohort study was obtained from a 10% random sample 
proportional to hospital size from the entire IBEAS Study 
population.
Methods This study compares the 1-day prevalence of 
the AEs obtained in the IBEAS Study with the incidence 
obtained through the retrospective cohort study.
results The prevalence of patients with AEs was 
10.47% (95% CI 9.90 to 11.03) (1191/11 379), while the 
cumulative incidence of the retrospective cohort study 
was 19.76% (95% CI 17.35% to 22.17%) (215/1088). In 
both studies the highest risk of suffering AEs was seen in 
Intensive Care Unit (ICU) patients. Comorbid patients and 
patients with medical devices showed higher risk.
conclusion The retrospective cohort design, although 
requires more resources, allows to detect more AEs than 
the cross-sectional design.
IntrOductIOn
Valid and timely information about the 
frequency and impact of healthcare related 
adverse events (AEs) and about the system’s 
ability to detect, prevent and manage these 
AEs is extremely important to understand the 
failures of healthcare, and to design and eval-
uate the effectiveness of risk reduction strate-
gies. Increasingly, a large number of research 
studies have estimated such type of informa-
tion in various health systems and organisa-
tional contexts,1 leading to a growing body 
of evidence about the burden and nature of 
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Research
strengths and limitation of this study
 ► The identification of adverse events (AEs)  is the 
first step to improve patient safety. We know cross-
sectional studies are easier and less expensive to 
measure AEs.
 ► This article adds the comparison between different 
study designs, and finds the most efficient to find 
AEs in the clinical practice. The study was made in 
five Latin American countries, so the data are strong 
for analysis.
 ► We learn with this study that retrospective cohort 
design allows to detect more AEs compared with 
cross-sectional. ICU patients and patients with 
comorbidities have more AEs.
 ► The sample used to evaluate the retrospective 
cohort was 10% of medical records used in the 
cross-sectional study, and proportional to hospital 
size, which could  not be representative of all the 
population attended to in the healthcare system. 
Tertiary hospitals are more complex and the number 
of AEs could be overestimated, in comparison with 
the total number of patients attended  to in the 
country.
 ► Another limitation is the quality of medical records. 
If the variabilities in the accomplishments between 
the different countries and healthcare systems were 
high the comparison between them could be weaker.
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AEs caused by healthcare. One of the most important 
sources of information for such type of data are the 
patients’ medical records, most frequently through the 
practice of retrospective reviews following agreed proto-
cols and standard abstract forms. This methodology has 
consolidated itself as one of the most valid references in 
the field of patient safety research.2 Nevertheless, despite 
the advantages of retrospective records reviews in identi-
fying important and observable AEs, there are also some 
concerns about the capacity to conduct such methodology 
in facilities with weaker data and research infrastructure, 
and moreover when certain periodicity is desirable for 
monitoring the effectiveness of risk reduction strategies.
Every research methodology and data collection system 
has its strengths and drawbacks.3 Routine information 
systems have limitations related to compliance and coding 
bias. Events reporting systems also show preference for 
the type of events that reporters consider more rele-
vant and have difficulties tracing duplicates, in addition 
to still facing unresolved legal issues in many contexts, 
which penalise reporting and limit their effective use. 
Prospective studies tend to focus on the analysis of high-
er-risk patients in detriment of other patients. Medical 
records, electronic or not, are threatened as well by lack 
of completeness and recording bias, since clinicians tend 
to record the data that are more meaningful to them 
from a clinical point of view. In addition, medical retro-
spective records review involves a sophisticated sampling 
plan, and a resource intensive process of record retrieval, 
reviewing and abstracting of sometimes very heavy and 
complex medical records.
A data collection process that has been less frequently 
used in the field of patient safety research, despite 
its potential, consists of running periodic cross-sec-
tional surveys aiming to assess the point prevalence of 
AEs.4 5, This design has been commonly used to monitor 
the frequency of healthcare associated infections in many 
hospitals across Europe and elsewhere,6 where it has 
proven to be a feasible and valid methodology, capable 
of being run with no excessive resources on a large scale 
and across many institutions and organisational cultures. 
One of the advantages of this design is that instead of 
requiring a statistically savvy sampling plan, all patients 
admitted at a given time to the hospital can be surveyed 
at once, simplifying the sampling process as well as the 
search and retrieval of records from the archives, since 
these are usually located near the patients in the wards.7 
This design also gives researchers the opportunity to ask 
the attending clinicians for some clarifications in the 
records, including some missing data. The unit of obser-
vation in this design is typically 1 day of admission, which 
makes it much shorter and simpler for the reviewers, and 
gives an estimate of a 1 day prevalence, as opposed to the 
cumulative incidence of a retrospective record review.8 
Because of its greater simplicity, the management of large 
and multicentred research studies is also simplified.
The IBEAS Study was a multicountry effort aiming to 
estimate for the first time the frequency of hospital related 
AEs in a selection of hospitals from Argentina, Colombia, 
Costa Rica, Mexico and Peru.9 The study was conducted in 
2007, in 58 hospitals of the five countries, with the collab-
oration of Spain, and pan-American organisation and 
WHO. It used a 1-day cross-sectional design due to the 
perceived simplicity, lesser demands and greater oppor-
tunities for strengthening local capacity and eventual 
replication of this approach. The researchers involved 
in designing IBEAS, aware of its innovative approach 
in the field of AE measurement, were mindful of deter-
mining the relationship between the estimates of the 
1-day point prevalence design and the more traditional 
retrospective cohort record review approach. In this same 
context Michel et al10 evaluated the rates comparing three 
different methods: cross-sectional, prospective and retro-
spective. Therefore, we selected a randomised sample of 
all IBEAS patients to fully examine retrospectively their 
medical records.
MethOds
The AE definitions used in both designs were those 
published by WHO in the International Classification for 
Patient Safety.11
A patient safety incident is an event or circumstance 
that could have resulted, or did result, in unnecessary 
harm to a patient.
An AE or harmful incident is an incident that results in 
harm to a patient.
Harm implies impairment of structure or function of 
the body and/or any deleterious effect arising therefrom, 
including disease, injury, suffering, disability and death, 
and may be physical, social or psychological.
In the IBEAS project the AE was defined as:9 'Any event 
causing harm to the patient that is perceived to be more 
related to the healthcare management rather than to the 
patient's underlying condition’.
The IBEAS Study had two parts,12 a cross-sectional study 
and a retrospective cohort study.
The cross-sectional study involved determining how 
many patients admitted to the participating hospitals 
experienced harmful incidents attributable to healthcare 
on a given day (day 0). A prevalent AE is defined as one 
that originates during hospitalisation and is clinically 
present on the day of the study, either as an after-effect 
or undertreatment. This also includes those AEs that 
were occasioned prior to hospitalisation at any care level 
and which led to subsequent admission. AEs that had 
occurred prior to the survey and whose effects had disap-
peared without prolonging the hospitalisation on that 
particular day were not included.
The retrospective cohort study was conducted using a 
sample of patients with the aim of confirming whether 
the cross-sectional study could replace the conventional 
retrospective cohort study used to date. Specifically, the 
study involved reviewing the case notes of a random 
sample of 10% of patients (1101 patients) hospitalised on 
day 0, proportional to hospital size, from the entire IBEAS 
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Figure 1 Study patients in the cross-sectional study.
Study population. Case notes were scanned to ascertain 
whether, at some point during their hospitalisation (or 
in a previous admission to the hospital), inpatients had 
experienced a harmful incident, regardless of whether 
the consequences of the incident were still present on day 
0. Patients continued to be monitored until discharge. 
The sampling strategy and forms are available on request. 
An incident AE is defined as one that occurs during any 
patient care process, as it may be detected at another level 
of care or in another hospital. In practical terms, as we 
carried out a retrospective study based on clinical hospital 
records, primary care AEs were not included. Those that 
led to readmission in the same or another hospital were 
compensated by the AEs which were detected during 
this hospitalisation and which had been originated in a 
previous hospitalisation.
The IBEAS Study was carried out in five countries: 
Argentina, Colombia, Costa Rica, Mexico and Peru. The 
number of hospitals included was 58, all of them second-
ary-level and tertiary-level hospitals. We used a purposive 
sample of hospitals and the inclusion was voluntary.
The sample size was of 11 379 patients, with a minimum 
of 2000 patients per country.
In both studies (cross-sectional and retrospective 
cohort), researchers used two tools to detect harmful inci-
dents, namely a Screening Guide and a Modular Ques-
tionnaire13 14 using the medical record review.15 16
First, the screening guide was applied to the patients in 
the study. This served as an alert and tracking system for 
possible incidents. All the patients admitted at hospital 
(except emergency room) were studied. The screening 
was made by well trained nurses.
If a patient screened positive for one or more of the 19 
alert criteria in the screening guide, the case was studied 
using the case history. An in-depth study of case histories 
enabled researchers to conclude whether a patient did in 
fact present with the consequences of a harmful incident 
(true positive) and if so, to classify the type of event, its 
severity, any associated factors, and whether or not the 
incident could have been avoided, and so on. This second 
confirmatory review was made (in both cross-sectional 
and retrospective) by medical doctors with at least 5 years 
of clinical experience. A patient could have more than 
one AE in the same hospitalisation, and in this case the 
study collects all of them.
The reviewers' training took place in two stages. First, 
the trainer workshop addressed the national coordi-
nating teams in Buenos Aires in 2007. Second, the 
national coordinators, in turn, trained the national inves-
tigators. A concordance study was carried out in Bogotá 
in 2008 using clinical records from each country. The 
most complex cases were assessed and an agreement was 
reached.
The preventable AE and the gravity were assessed 
according to the recommendations in the Modular Ques-
tionnaire, and the reviewers were also trained in these 
criteria.
The cross-sectional and the retrospective cohort 
studies were made by the same reviewers in each country.
The completed review forms of the retrospective 
study were entered in electronic files and submitted to a 
central repository managed exclusively by the principal 
investigators. Descriptive and multivariate analyses were 
conducted using SPSS V.14. Logistic regressions were 
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Figure 2 Study patients in the retrospective cohort study.
used to estimate the prevalence and incidence of AEs, 
once taking into account the effect of some covariates, 
such as patient’s age and comorbidity (intrinsic factors), 
presence of catheter lines and medical devices (extrinsic 
factors), type of admission and type of hospital. 
results
In the cross-sectional study 11 379 patients were included 
(figure 1); 3853 of them (33.9%) fulfilled at least one 
of the screening criteria. In the second phase of the 
cross-sectional study 1191 patients had an AE.
For the retrospective cohort study (figure 2), 1101 
patients (10%) were randomly selected from all the 
11 379 patients included in the cross-sectional study. The 
medical records of 13 of these patients (1.2%) could not 
be retrieved and were excluded from the study.
The screening phase of the retrospective review found 
about 44.5% of the medical records, corresponding to 
484 patients, positive for at least one of the 19 triggers 
included in the forms. At the confirmatory phase, it was 
determined that 40 of those patients had experienced 
one or more patient safety incidents without harm or 
prolonged stay, and 288 patients had experienced at least 
one AE (harmful patient safety incident). Of these, in 215 
patients the AE was considered to be mostly related to the 
healthcare received rather than to the patient intrinsic 
vulnerability.
The characteristics of patients in the two types of study 
are presented in table 1. Patients in the retrospective 
cohort study were of similar sex composition than the 
cross-sectional study sample. Though they were slightly 
older, they did not show significant differences in their 
intrinsic factors (comorbidity). It seemed there were 
more patients in surgical wards and with slightly more 
procedures in the retrospective review sample than the 
patients in the 1-day cross-sectional study. The composi-
tion of participating hospitals and type of admission was 
comparable in the two types of designs.
Table 2 shows the prevalence of patients with AEs was 
10.47% (95% CI 9.90% to 11.03%). As a patient can have 
more than one AE, the total number of AEs detected 
was 1349, so the global prevalence of AEs was 11.85% 
(1349/11379) (95% CI 11.26% to 12.46%).
Table 2 also shows the cumulative incidence of patients 
suffering at least one AE related to the care received 
before or during their hospitalisation was 19.76% (95% 
CI 17.35% to 22.17%) (215/1088). In total, there were 
314 AEs (because a patient could have more than 1 AE) 
related to healthcare corresponding to a cumulative inci-
dence of total AEs of 28.86% (95% CI 26.12% to 31.60%) 
(317/1088).
Table 3 shows the results of the cross-sectional study 
and the retrospective cohort record review per country, 
showing the rate of positive screening and its positive 
predictive value (PPV) and the corresponding final esti-
mate in terms of 1-day prevalence and the proportion 
of patients with at least one AE during their hospitalisa-
tion. In the 1-day cross-sectional study, the rate of posi-
tive screening review form (SRF) seemed to range more 
homogeneouslybetween 30% to 39% of all records, with 
PPVs between 25% and 37%. In the retrospective cohort 
review, however, the range of positive screening was wider 
going from about 17% to almost 64% of all records, 
and also reaching higher PPVs from 24% to over 60%. 
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Table 1 Characteristics of the study population
Cross-sectional Retrospective cohort p Value
n % 95% CI n % 95% CI
Sex Women 5975 52.5 51.6 to 53.4 547 50.3 47.3 to 53.2 n.s.
Age Mean (SD) 40.2 26.9 42.1 26 31.3 to 36.9 0.02
Department Medical wards 4045 35.5 34.7 to 36.4 371 34.1 31.3 to 36.9 .001
Surgery/gynaecology 3898 34.3 33.4 to 35.1 435 40.0 37.1 to 42.9
Obstetrics 1241 10.9 10.3 to 11.5 109 10.0 8.2 to 11.8
Paediatrics 1701 14.9 14.3 to 15.6 128 11.8 9.9 to 13.7
Intensive care 494 4.3 4 to 4.7 45 4.1 3 to 5.3
Hospital complexity Tertiary 10 520 92.5 92 to 92.9 1011 92.9 91.4 to 94.4 n.s.
Secondary
(with surgery and ICU 
wards)
859 7.5 7.1 to 8 77 7.1 5.6 to 8.6
Admission type Unplanned admission 8031 70.6 69.7 to 71.4 726 66.7 63.9 to 69.5 n.s.
Planned admission 2099 18.4 17.7 to 19.2 190 17.4 15.2 to 19.7
Intrinsic risk factors Yes 6128 53.9 52 to 54.8 615 56.5 53.6 to 5.5 n.s.
No 5251 46.1 45.2 to 47.1 473 43.5 40.5 to 46.4
Extrinsic risk factors Yes 8484 74.6 73.8 to 75.4 844 77.6 75.1 to 80.1 0.03
No 2895 25.4 24.6 to 26.2 244 22.4 19.9 to 24.9
Patients studied 11 379 1088
n.s., not significant (p>0.05).





Patients with adverse events (AEs) 1191/11379=10.47%
(95% CI 9.90% to 11.03%)
215/1088=19.76%
(95% CI 17.35% to 22.17%)
Total number of AEs 1349/11379=11.85%
(95% CI 11.26% to 12.46%)
314/1088=28.86%
(95% CI 26.12% to 31.61%)
In all countries, the percentage of patients suffering at 
least one AE during their hospitalisation was significantly 
higher than the rate observed in the 1-day study, with 
values going from 11% of patients to more than 36%.
In both studies (table 4), the highest risk of suffering 
AEs was seen in ICU patients. Surgical patients were 
associated with more risk than patients admitted in the 
medical wards. Whereas, in the cross-sectional study, 
obstetrics and paediatric patients also showed higher risk 
than medical patients. Comorbid patients showed higher 
risk of suffering AEs in both studies, as well as patients 
with catheter lines, and other procedures. Similarly, the 
length of stay before the day of study in the cross-sectional 
study and the total length of stay in the retrospective 
cohort were associated witha higher risk of suffering AE. 
In the retrospective cohort review, emergency hospitalisa-
tions did not seem to be associated to the risk of suffering 
AEs as seemed to be the case in the cross-sectional study. 
Patient age was not retained as an independent variable 
or as a confounding factor in the final model in both 
studies.
Reference categories: (1) medical specialities; (2) 
secondary hospitals of intermediate complexity with at 
least surgical theatres, and postsurgical resuscitation 
wards; (3) planned admission; (4) no comorbidities (5) 
no devices .
The types of AEs identified in both the cross-sectional 
and the retrospective cohort studies showed similar distri-
bution. The most frequent types of AEs identified in any 
study were related to the occurrence of healthcare associ-
ated infections (more than 35% of all AEs), followed by 
AEs related to procedures (more than 26%). Medication 
related AEs represented less than 10% of all AEs in each 
of the studies (table 5).
There were some differences in the impact caused by 
the AEs identified in the cross-sectional study, versus the 
retrospective cohort study. The AEs identified through 
the cross-sectional study seemed to be associated more 
frequently with hospital readmissions and slightly more 
with prolonged stay, whereas the frequency of AEs which 
did not cause prolonged stay or readmission was higher 
in the retrospective cohort study (table 6).
group.bmj.com on November 15, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
6 Aranaz Andrés JM, et al. BMJ Open 2017;7:e016546. doi:10.1136/bmjopen-2017-016546
Open Access 
Table 3 Adverse event frequency measures and screening form performance































































































































































(95% CI 17.3% to 
22.2%)
Table 4 Correlates of adverse events in multiple logistic regression analyses
Cross-sectional Retrospective cohort
Variables p Value OR 95% CI for OR p Value OR 95% CI for OR
Department (1)
Surgery and gynaecology 0.06 1.17 0.99 1.38 0.01 1.75 1.17 2.61
Obstetrics 0.02 1.37 1.06 1.78 0.05 0.38 0.15 0.99
Paediatrics 0.00 1.50 1.21 1.85 0.15 0.40 0.12 1.40
Intensive care 0.00 2.52 1.96 3.26 0.01 2.77 1.25 6.17
Complexity of the hospital (2) tertiary 0.02 1.45 1.07 1.97
Type of admission (3) urgent 0.00 1.34 1.12 1.61 0.59 1.14 0.71 1.83
Length of stay until the day of study 0.03 1.00 1.00 1.00 0.01 1.00 1.00 1.01
Patient comorbidity (4) any 0.00 1.42 1.22 1.64 0.00 2.02 1.28 3.19
Use of medical devices (5) any 0.00 2.59 2.14 3.14 0.00 3.24 1.79 5.85
Country 1
Country 2 0.00 0.46 0.38 0.56 0.00 0.34 0.20 0.59
Country 3 0.37 0.91 0.73 1.12 0.16 1.44 0.86 2.41
Country 4 0.00 0.65 0.52 0.81 0.00 0.22 0.12 0.42
Country 5 0.04 0.82 0.69 0.99 0.01 0.38 0.19 0.76
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Table 5 Adverse event (AE) types and proportion of total AE
Type of AE Prevalence 95% CI
Cumulative 
incidence 95% CI
Care provided 13.27% 11.46 to 15.08 12.16% 16.24 to 20.32
Medication 8.23% 6.76 to 9.69 6.57% 9.87 to 13.17
Healthcare associated infections 37.14% 34.56 to 39.72 30.68% 35.99 to 41.30
Related to procedures 28.69% 26.27 to 31.10 21.86% 26.75 to 31.65
Diagnostic issues 6.15% 6.15 to 7.44 2.66% 5.10 to 7.53
Nosocomial urinary tract infection 4.08% 2.98 to 5.17 5.09% 2.50 to 7.69
Nosocomial pneumonia 9.41% 7.82 to 11.01 6.37% 3.51 to 9.23
Postsurgical haematoma 2.89% 1.96 to 3.82 3.50% 1.31 to 5.69
Phlebitis 3.41% 2.40 to 4.41 5.73% 3.00 to 8.46
Neonatal complications 1.12% 0.51 to 1.71 0.32% 0.01 to 1.76
Table 6 Impact of adverse events in hospitalisation, n (%)
Cross-sectional Retrospective cohort
Did not have prolonged 
hospital stay 228 18.91% (95% CI 16.65% to 21.16%) 87 29.9% (95% CI 24.46% to 35.33%)
Prolonged hospital stay 759 62.9% (95% CI 60.17% to 65.70%) 178 61.2% (95% CI 51.88% to 63.58%)
Extra days same 
hospitalisation
Mean: 16.1 days SD (29.6) Mean: 14.9 days SD (19.9)
Causing admission 219 18.16% (95% CI 15.94% to 20.38%) 26 8.9% (95% CI 5.48% to 12.38%)
Extra days new 
hospitalisation
Mean: 21.4 days SD (69.7) Mean:19.0 days SE (22.3)
The preventability of AE (See online supplementary 
appendix) was very similar, with about 65% in the retro-
spective cohort review and 60% for the cross-sectional 
study.
dIscussIOn
The choice of the most appropriate epidemiological 
design in the study of magnitude of AE is not a trivial issue. 
The question has been analysed in different studies and 
the generalised consensus is that the choice of method 
should be based on the aims of the study and the need 
to combine the minimisation of bias and the validity of 
AE identification with the reproducibility of value judge-
ments on their iatrogenic nature and/or preventability.17
The retrospective design for the study of AE has been 
the method used in all national studies.1 Nevertheless it 
is a method which produces results which may be heavily 
influenced by the quality of clinical records.
A prospective study offers pedagogical and commu-
nicative advantages and facilitates a concomitant anal-
ysis of the root causes which provide the conditions for 
the occurrence of AEs. However not only might it prove 
too costly, but it would also involve a high workload and 
excessive complexity.
On the other hand, the cross-sectional design is 
more time-efficient and resource-efficient and easier to 
perform. Although it does not allow for a study of the 
total hospitalisation episode, it has proved capable of 
sustaining over time a more stable system of observation. 
We also need to bear in mind that, as a result of a possible 
survival bias, those AEs which lead to hospital admission 
will be over-represented, as will those related to nosoco-
mial infection or those which are difficult to identify if 
the patient is not examined (such as bruising), due to the 
systemic approach itself of a prevalence study. As in the 
prospective approach, communication with the ward staff 
(the patient is hospitalised at this time) makes it easier to 
judge the causality of the AE and its preventability.
The relationship between prevalence and incidence 
generally depends on the duration of the event under 
review and the period of observation.8 In our case we 
calculated prevalence on a given day and not during the 
whole period. Consequently this relationship will not be 
well reflected. In figure 3 we see the possible AEs which 
may occur and those that are detected on the basis of this 
approach.
When we compare the results of the cross-sectional 
study with those of the retrospective cohort study within 
the context of the IBEAS project, the differences are due 
exclusively to the design, as the methodology and sample 
are the same (assuming the representativeness of the 
incidence subcohort). In (online supplementary appen
dix), figure 3 and figure 4) which represent the scheme 
followed in the methodology of this study, we see that 
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Figure 3 Study of prevalent AE on a given day. AE, adverse event; HCC, healthcare centre; PC, primary care.
Figure 4 Scheme of incident AE study. AE, adverse event; HCC, healthcare centre; PC, primary care.
the difference between the prevalence and incidence 
values on a given day are due to those AEs which, having 
occurred during hospitalisation, are not prevalent on 
the day of the study (represented by a yellow arrow in 
figure 3). This also explains why the patients of the retro-
spective cohort study present more extrinsic risk factors 
(devices) than in the cross-sectional study.
The SRF has been used in American18 19  and Austra-
lian20 21 cohort studies and in different European22 23 
countries. It is highly sensitive (84%) in the detection of 
AEs and we therefore assume that the number of false 
negatives should be small. We can also detect with the 
revision of the modular questionnaire.
Appropriateness of the review forms to a point prev-
alence study was discussed during the training work-
shop. Modifications to adapt them to the context of 
Latin America were done bearing in mind vocabu-
lary, and adding common risk factors like malaria or 
prematurity.
The percentage of patients flagged in the SRF and the 
predictive value of this phase in the detection of AE are 
totally compatible with those found in those other AE 
studies of which we are aware. We can therefore state that 
the materials are sensitive enough and appropriate for 
the identification of both prevalence and cumulative inci-
dence of AE. However, in the retrospective cohort study, 
the PPV of the SRF is higher. This may be due to the fact 
either that the guide was originally designed for an inci-
dence study and proves more efficient in this type of study 
or that as the retrospective cohort study was performed 
after the cross-sectional study, it is possible that the expe-
rience of the reviewers raised the performance level of 
the first questionnaire.
The Spanish version of the modular review form was 
adapted in Spain for the Identification of Adverse Events 
(IDEA) Project and modified after the ENEAS (National 
Study of Adverse Events) Study.4 The researcher must 
make value judgements through implicit criteria on most 
occasions. Characterisation of AEs caused by the care 
rather than the pathological process itself, is done by the 
reviewer scoring from 1 to 6 the probability that the AE is 
due to the care. A value of ≥4 is required to confirm this. 
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The same criterion is used to evaluate the AE as prevent-
able. Cross-sectional design allows researchers to consult 
the medical staff while they are collecting data in order to 
clarify any uncertainty or doubts associated with the AE. 
The reliability of the questionnaire in other studies has 
been assessed as moderate.23
A limitation of this study could be the sample used to 
evaluate the retrospective cohort. It is 10% of medical 
records used in the cross-sectional study and proportional 
to hospital size, which could be not representative of all 
the population attended to in the healthcare system. 
Tertiary hospitals have more complexity and the number 
of AEs could be overestimated, in comparison with the 
total number of patients attended to in the country. 
Another limitation is the quality of medical records. If the 
variability in the accomplishment between the different 
countries were high the comparison between them could 
be weaker.
The frequency of AEs in both the cross-sectional and 
retrospective cohort studies was greater than that found 
in previous studies, which may be due to the different 
characteristics of the patients, who had higher average 
age and more risk factors. The nature of the sample selec-
tion and the peculiarities of the different search systems 
prevent statistical inferences and comparisons either 
within each country or between the countries which are 
part of the study.
In any case, higher prevalence means higher cumula-
tive incidence. In some way the interdependence of these 
frequency measures remains when we use prevalence 
on a given day. The fact that prevalence is sensitive to 
the differences in the characteristics of the patients and 
that it reflects the differences found between countries, 
would make it a useful tool in the study and follow-up of 
the frequency of AEs and in comparative studies. Further-
more, as the explanatory model for the occurrence of AE is 
the same, studying the factors which influence prevalence 
may provide the same clues when designing strategies for 
AE control and therefore provide a more efficient tool.
Moreover, the fact that the prevalence design detects 
proportionally more serious AEs is not a drawback. On 
the contrary, these are precisely the AEs which need to 
be prioritised when designing control strategies, and as 
we commented above, the detected AEs were equally 
preventable in both designs. This reinforces the idea that 
preventability and seriousness of the AEs are indepen-
dent factors.
Due to the fact that the point prevalence design is more 
efficient in terms of time and resources, its validity is less 
dependent on the quality of the clinical records and 
allows simultaneous study through other observation and 
audit systems, regular prevalence on a given day studies 
might provide an efficient AE monitoring and control 
strategy.
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